AZD5335

Phase 3Small molecule

AstraZeneca

AZD5335 is one of 79 small molecule programs targeting Fallopian Tube Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Fallopian Tube CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Fallopian Tube CancerPhase 1

Active, not recruiting

Ovarian CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

836 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Hycamtin

MMeitheal

Phase 3

28 2

Imfinzi

AstraZeneca

Phase 3

8 3

Votrient

Novartis

Phase 3

8 4

Perjeta

Roche

Phase 3

3 5

Trodelvy

Gilead

Phase 3

3 6

Bavencio

EMD Serono

Phase 3

7 7

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

1 8

TLK286

TTelik

Phase 3

5 9

INCB123667

Incyte

Phase 3

2 10

AZD5335

AstraZeneca

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Fallopian Tube Cancer

NCT07402915

Q1 2028

Phase 1/2Recruiting

Combination Therapy

NCT05797168

Q2 2030

Phase 3Recruiting

Ovarian Cancer

NCT07218809

Clinical

Trials by Indication[1]

Ovarian Cancer1 trial

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07218809·1,100 enrolled

Combination Therapy1 trial

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

Recruiting· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT05797168·506 enrolled

Fallopian Tube Cancer1 trial

An Open-label, Fixed Sequence Phase I Study to Evaluate the Effect of Itraconazole (a Strong CYP3A Inhibitor) on the Pharmacokinetics of AZ14170132, the TOP1 Inhibitor Payload of the Antibody Drug Conjugate AZD5335, in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT07402915·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for AZD5335. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD5335 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD5335. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

AZD5335

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2028

Q2 2030

Trials by Indication[1]

Ovarian Cancer1 trial

Combination Therapy1 trial

Fallopian Tube Cancer1 trial

References

Drug Info

Quick Facts

Related News